Technical Roundup on Healthcare Stocks -- ResMed, MiMedx, Varian Medical Systems, and Accuray

Sep 16, 2016, 07:55 ET from Chelmsford Park SA

NEW YORK, September 16, 2016 /PRNewswire/ --

The Medical Appliances and Equipment space was the third largest of the selected industries in 2015 with the Americas being its biggest geographical market, Europe as its second, and Asia as the third. The industry belongs to the Healthcare sector, which was up 1.5% as of midday Thursday. This morning, reviews the recent performances of the following equities: ResMed Inc. (NYSE: RMD), MiMedx Group Inc. (NASDAQ: MDXG), Varian Medical Systems Inc. (NYSE: VAR), and Accuray Inc. (NASDAQ: ARAY). Sign up today and download for free the research reports for the stocks covered today at:


San Diego, California headquartered ResMed Inc.'s stock finished Thursday's session at $64.96, climbing 0.14%. A total volume of 1.07 million shares was traded, which was above their three months average volume of 939,760 shares. Over the previous three months and start of this year, the Company's shares have gained 11.11% and 22.84%, respectively. The stock is trading above its 200-day moving average by 9.17%. Moreover, shares of ResMed, which designs, develops, manufactures, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders, have a Relative Strength Index (RSI) of 37.64.

On August 23rd, 2016, research firm Jefferies downgraded the Company's stock rating from 'Hold' to 'Underperform'.

On September 6th, 2016, ResMed announced positive results from the independent Home Oxygen Therapy- Home Mechanical Ventilation (HOT-HMV) study regarding the benefits of home non-invasive ventilation (NIV). The HOT-HMV study shows that the addition of home NIV to home oxygen therapy improves admission-free survival in hypercapnic COPD patients (those with high levels of carbon dioxide in the blood) following a life-threatening exacerbation of COPD requiring acute NIV. RMD complete research report is just a click away at:

MiMedx Group  

Shares in Marietta, Georgia headquartered MiMedx Group Inc. ended yesterday's session 3.45% higher at $8.99. A total volume of 1.09 million shares was traded, which was higher than their three months average volume of 825,390 shares. The stock has gained 21.32% in the past month and 17.98% in the previous three months. The Company's shares are trading 16.97% above their 50-day moving average and 11.53% above their 200-day moving average. Moreover, shares of MiMedx, which develops, processes, and markets patent protected and proprietary regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues, and human skin and bone, have an RSI of 72.42.

On September 15th, 2016, MiMedx Group announced that the Company urged the Food and Drug Administration ("FDA") to reconsider its Draft Guidances on Minimal Manipulation and Homologous Use of Human Cells, Tissues, and Cellular and Tissue Based Products (HCT/Ps) during hearings conducted on September 12th and 13th, 2016. An overwhelming majority of the parties, who testified at the hearing, including the American Association of Tissue Banks, called for notice and comment rulemaking or stated that the Draft Guidances constitute major changes to the current regulatory scheme. The complimentary report on MDXG can be downloaded at:

Varian Medical Systems  

On Thursday, Palo Alto, California headquartered Varian Medical Systems Inc.'s stock rose 1.66%, to close the day at $96.15. A total volume of 515,462 shares was traded. The Company's shares have advanced 2.68% in the last one month, 17.53% in the previous three months, and 19.00% on an YTD basis. The stock is trading 4.21% above its 50-day moving average and 15.60% above its 200-day moving average. Additionally, shares of Varian Medical Systems, which designs, manufactures, sells, and services medical devices and software products for treating cancer and other medical conditions worldwide, have an RSI of 59.06.

On September 15th, 2016, the company announced it has received 510(k) clearance from the FDA to market the Nexus DR, a high resolution imaging system for X-ray imaging using a digital X-ray detector. The Nexus DR is designed to replace conventional film techniques, or existing digital systems, in multipurpose or dedicated applications. Sign up for your complimentary report on VAR at:


Shares in Sunnyvale, California headquartered Accuray Inc. ended the day 0.36% lower at $5.46 and with a total trading volume of 525,031 shares. The stock has gained 6.64% in the previous three months. The Company's shares are trading above their 50-day moving average by 1.36%. Furthermore, shares of Accuray, which designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body, have an RSI of 52.52.

On August 17th, 2016, Accuray reported that gross product orders totaled $95.4 million for Q4 FY16, an increase 12% from Q4 FY15. Total revenue was $95.0 million in Q4 FY16 compared to $101.8 million in Q4 FY15. For Q4 FY16, net loss was $7.2 million, or $0.09 per share, compared to a net loss of $5.6 million, or $0.07 per share, for Q4 FY15. Download the research report for free on ARAY at:


Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA